Malaysian (KLSE) Pharma Industry Analysis
UpdatedJun 07, 2023
DataAggregated Company Financials
Companies6
- 7D-1.8%
- 3M-5.7%
- 1Y17.8%
- YTD-5.6%
Over the last 7 days, the Pharma industry has dropped 1.8%, driven by Duopharma Biotech Berhad declining 2.9%. This takes the industry's 12 month performance to a gain of 18%. In the next few years earnings are forecast to be pretty stable.
Industry Valuation and Performance
Has the Malaysian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 07 Jun 2023 | RM4.5b | RM2.6b | RM304.7m | 14.7x | 14.9x | 1.8x |
| Fri, 05 May 2023 | RM4.6b | RM2.5b | RM289.8m | 13.6x | 16x | 1.9x |
| Sun, 02 Apr 2023 | RM4.8b | RM2.5b | RM289.8m | 13.1x | 16.5x | 1.9x |
| Tue, 28 Feb 2023 | RM4.9b | RM2.5b | RM288.7m | 13.2x | 17x | 2x |
| Thu, 26 Jan 2023 | RM4.7b | RM2.4b | RM270.7m | 13x | 17.2x | 1.9x |
| Sat, 24 Dec 2022 | RM4.7b | RM2.4b | RM270.7m | 13.4x | 17.5x | 1.9x |
| Mon, 21 Nov 2022 | RM4.2b | RM2.4b | RM261.3m | 12.5x | 16.2x | 1.7x |
| Wed, 19 Oct 2022 | RM4.0b | RM2.4b | RM249.0m | 11.6x | 15.9x | 1.7x |
| Fri, 16 Sep 2022 | RM4.0b | RM2.4b | RM249.0m | 11.8x | 16.1x | 1.7x |
| Sun, 14 Aug 2022 | RM3.9b | RM2.3b | RM226.0m | 14.2x | 17x | 1.7x |
| Tue, 12 Jul 2022 | RM3.5b | RM2.3b | RM226.0m | 13.8x | 15.6x | 1.5x |
| Thu, 09 Jun 2022 | RM3.8b | RM2.3b | RM226.0m | 14.2x | 17x | 1.7x |
| Sat, 07 May 2022 | RM4.0b | RM2.2b | RM204.5m | 16.5x | 19.3x | 1.8x |
| Mon, 04 Apr 2022 | RM3.9b | RM2.2b | RM204.5m | 16.2x | 19.3x | 1.8x |
| Wed, 02 Mar 2022 | RM3.8b | RM2.2b | RM203.8m | 15.8x | 18.8x | 1.7x |
| Fri, 28 Jan 2022 | RM3.5b | RM2.1b | RM187.4m | 15.5x | 18.9x | 1.7x |
| Sun, 26 Dec 2021 | RM3.7b | RM2.1b | RM187.4m | 15.4x | 19.6x | 1.7x |
| Tue, 23 Nov 2021 | RM3.7b | RM2.1b | RM170.6m | 20.5x | 22x | 1.8x |
| Thu, 21 Oct 2021 | RM3.9b | RM2.0b | RM166.6m | 21x | 23.5x | 1.9x |
| Sat, 18 Sep 2021 | RM4.0b | RM2.0b | RM166.5m | 20.5x | 24.2x | 2x |
| Mon, 16 Aug 2021 | RM3.9b | RM2.0b | RM166.5m | 19.3x | 23.3x | 1.9x |
| Mon, 31 May 2021 | RM4.6b | RM2.0b | RM167.4m | 17.8x | 27.4x | 2.3x |
| Thu, 04 Mar 2021 | RM4.6b | RM1.9b | RM169.0m | 19.2x | 27.4x | 2.4x |
| Sun, 06 Dec 2020 | RM5.6b | RM2.0b | RM169.6m | 17.7x | 33.1x | 2.9x |
| Wed, 09 Sep 2020 | RM5.3b | RM2.0b | RM180.8m | 16.9x | 29.3x | 2.7x |
Price to Earnings Ratio
18.5x
Current Industry PE
- Investors are pessimistic on the Malaysian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 14.9x which is lower than its 3-year average PE of 21.8x.
- The 3-year average PS ratio of 2.0x is higher than the industry's current PS ratio of 1.8x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have grown 19% per year over the last three years.
- Revenues for these companies have grown 9.0% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Malaysian Healthcare industry?
| MY Market | -1.02% | |
| Healthcare | 1.17% | |
| Pharma | -1.76% | |
| Pharma | -1.76% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| RHONEMA Rhone Ma Holdings Berhad | RM0.76 | 4.1% +RM6.6m | 4.9% | PE13.5x | |
| YSPSAH Y.S.P. Southeast Asia Holding Berhad | RM2.55 | 1.2% +RM4.2m | 28.8% | PE9.3x |